What are the National Comprehensive Cancer Network (NCCN) treatment guidelines for higher-risk myelodysplastic syndrome (MDS)?

Updated: Jul 24, 2018
  • Author: Emmanuel C Besa, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
  • Print

NCCN guidelines recommendations for treatment of higher-risk MDS include the following [24] :

  • Allogeneic hematopoietic stem cell transplant (HSCT)
  • For non-transplant candidates or for candidates with no response or relapse after transplantation, azacitidine (preferred; category 1) or decitabine

The ESMO and ELN guidelines offer similar recommendations. [40, 39]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!